                               SEQUENCE LISTING

<110> CELLA THERAPEUTICS, INC.
 
<120> DRUG DELIVERY SYSTEMS COMPRISING AN INTRAOCULAR PRESSURE LOWERING
      AGENT, A CNP COMPOUND, AN NPR-B COMPOUND, A TIE-2 AGONIST, OR 
      NEUROTROPHIC AGENT FOR TREATING GLAUCOMA OR OCULAR HYPERTENSION

<130> V3563.10001WO01

<140>
<141>

<150> 62/747,060
<151> 2018-10-17

<150> 62/726,029
<151> 2018-08-31

<150> 62/687,172
<151> 2018-06-19

<160> 15    

<170> PatentIn version 3.5

<210> 1
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 1
Val Gly Asp Gly Gly Leu Phe Glu Lys Lys Leu 
1               5                   10      


<210> 2
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 2
Asp Gly Gly Leu Gly 
1               5   


<210> 3
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 3
His His Ile Tyr Leu Gly Ala Val Asn Tyr Ile Tyr 
1               5                   10          


<210> 4
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 4
His His Ile Tyr Leu Gly Ala Thr Asn Tyr Ile Tyr 
1               5                   10          


<210> 5
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 5
Tyr Leu Gly Ala 
1               


<210> 6
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 6
Ile Tyr Leu Gly Ala 
1               5   


<210> 7
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 7
Tyr Leu Gly Ala Val 
1               5   


<210> 8
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 8
His Ile Tyr Leu Gly Ala 
1               5       


<210> 9
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 9
Ile Tyr Leu Gly Ala Val 
1               5       


<210> 10
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 10
His Ile Tyr Leu Gly Ala Val 
1               5           


<210> 11
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 11
Ile Tyr Leu Gly Ala Val Asn 
1               5           


<210> 12
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 12
His His Ile Tyr Leu Gly Ala 
1               5           


<210> 13
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 13
Tyr Leu Gly Ala Val Asn Tyr 
1               5           


<210> 14
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 14
His His Ile Tyr Leu Gly Ala Val 
1               5               


<210> 15
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 15
Tyr Leu Gly Ala Val Asn Tyr Ile 
1               5               


